Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection

Karolien E. Goffin, Steven Joniau, P. Tenke, Kevin Slawin, Eric A. Klein, Nancy Stambler, Thomas Strack, John Babich, Thomas Armor, Vivien Wong

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

99mTc-trofolastat (99mTc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen, shows high potential to detect prostate cancer (PCa) noninvasively using SPECT. We therefore wanted to assess the performance of 99mTc-trofolastat SPECT/CT in a phase 2 multicenter, multireader prospective study in patients with intermediate- and high-grade PCa, before radical prostatectomy and extended pelvic lymph node (LN) dissection, with histopathology as the gold standard. Methods: PCa patients (n = 105) with an increased risk of LN involvement (LNI) underwent pelvic 99mTc-trofolastat SPECT/CT before radical prostatectomy with extended pelvic LN dissection. The sensitivity of 99mTc-trofolastat for detection of PCa on a patient and lobe basis, using visual and semiquantitative (tumor-to-background ratio [TBR]) scores, and of LNI was evaluated as well as the correlation of uptake within the gland to Gleason scores (GS) and assessment of the predictive potential of 99mTc-trofolastat uptake for LNI. Results: PCa was detected in 98 patients (94%) with acceptable variability between readers. There was a significantly higher visual score and TBR in positive lobes compared with tumor-negative lobes. Receiver-operating characteristic analysis showed that visual scores more accurately discriminated lobes with GS # 3 1 3 from ≥ 3 1 4, whereas TBRs discriminated high-grade disease from normal lobes better. Visual scores and TBRs correlated significantly with GS. 99mTc-trofolastat SPECT/CT detected LNI with a sensitivity of 50% and specificity of 87%, and TBR values significantly predicted LNI with a sensitivity of 90%. Conclusion: 99mTc-trofolastat SPECT/CT detects PCa with high sensitivity in patients with intermediate- and high-risk PCa compared with histology. It has the potential to be used as a surrogate marker for GS and predict LNI.

Original languageEnglish
Pages (from-to)1408-1413
Number of pages6
JournalJournal of Nuclear Medicine
Volume58
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Prostatectomy
Lymph Node Excision
Prostatic Neoplasms
Neoplasm Grading
Single Photon Emission Computed Tomography Computed Tomography
Single-Photon Emission-Computed Tomography
ROC Curve
Neoplasms
Histology
Biomarkers
Lymph Nodes
Prospective Studies
Sensitivity and Specificity

Keywords

  • Tc-trofolastat (Tc-MIP-1404)
  • Histopathology
  • Prostate cancer
  • SPECT/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection. / Goffin, Karolien E.; Joniau, Steven; Tenke, P.; Slawin, Kevin; Klein, Eric A.; Stambler, Nancy; Strack, Thomas; Babich, John; Armor, Thomas; Wong, Vivien.

In: Journal of Nuclear Medicine, Vol. 58, No. 9, 01.09.2017, p. 1408-1413.

Research output: Contribution to journalArticle

Goffin, Karolien E. ; Joniau, Steven ; Tenke, P. ; Slawin, Kevin ; Klein, Eric A. ; Stambler, Nancy ; Strack, Thomas ; Babich, John ; Armor, Thomas ; Wong, Vivien. / Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection. In: Journal of Nuclear Medicine. 2017 ; Vol. 58, No. 9. pp. 1408-1413.
@article{8ade41a569d94f8d8723e8aa4feafcc8,
title = "Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection",
abstract = "99mTc-trofolastat (99mTc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen, shows high potential to detect prostate cancer (PCa) noninvasively using SPECT. We therefore wanted to assess the performance of 99mTc-trofolastat SPECT/CT in a phase 2 multicenter, multireader prospective study in patients with intermediate- and high-grade PCa, before radical prostatectomy and extended pelvic lymph node (LN) dissection, with histopathology as the gold standard. Methods: PCa patients (n = 105) with an increased risk of LN involvement (LNI) underwent pelvic 99mTc-trofolastat SPECT/CT before radical prostatectomy with extended pelvic LN dissection. The sensitivity of 99mTc-trofolastat for detection of PCa on a patient and lobe basis, using visual and semiquantitative (tumor-to-background ratio [TBR]) scores, and of LNI was evaluated as well as the correlation of uptake within the gland to Gleason scores (GS) and assessment of the predictive potential of 99mTc-trofolastat uptake for LNI. Results: PCa was detected in 98 patients (94{\%}) with acceptable variability between readers. There was a significantly higher visual score and TBR in positive lobes compared with tumor-negative lobes. Receiver-operating characteristic analysis showed that visual scores more accurately discriminated lobes with GS # 3 1 3 from ≥ 3 1 4, whereas TBRs discriminated high-grade disease from normal lobes better. Visual scores and TBRs correlated significantly with GS. 99mTc-trofolastat SPECT/CT detected LNI with a sensitivity of 50{\%} and specificity of 87{\%}, and TBR values significantly predicted LNI with a sensitivity of 90{\%}. Conclusion: 99mTc-trofolastat SPECT/CT detects PCa with high sensitivity in patients with intermediate- and high-risk PCa compared with histology. It has the potential to be used as a surrogate marker for GS and predict LNI.",
keywords = "Tc-trofolastat (Tc-MIP-1404), Histopathology, Prostate cancer, SPECT/CT",
author = "Goffin, {Karolien E.} and Steven Joniau and P. Tenke and Kevin Slawin and Klein, {Eric A.} and Nancy Stambler and Thomas Strack and John Babich and Thomas Armor and Vivien Wong",
year = "2017",
month = "9",
day = "1",
doi = "10.2967/jnumed.116.187807",
language = "English",
volume = "58",
pages = "1408--1413",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "9",

}

TY - JOUR

T1 - Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection

AU - Goffin, Karolien E.

AU - Joniau, Steven

AU - Tenke, P.

AU - Slawin, Kevin

AU - Klein, Eric A.

AU - Stambler, Nancy

AU - Strack, Thomas

AU - Babich, John

AU - Armor, Thomas

AU - Wong, Vivien

PY - 2017/9/1

Y1 - 2017/9/1

N2 - 99mTc-trofolastat (99mTc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen, shows high potential to detect prostate cancer (PCa) noninvasively using SPECT. We therefore wanted to assess the performance of 99mTc-trofolastat SPECT/CT in a phase 2 multicenter, multireader prospective study in patients with intermediate- and high-grade PCa, before radical prostatectomy and extended pelvic lymph node (LN) dissection, with histopathology as the gold standard. Methods: PCa patients (n = 105) with an increased risk of LN involvement (LNI) underwent pelvic 99mTc-trofolastat SPECT/CT before radical prostatectomy with extended pelvic LN dissection. The sensitivity of 99mTc-trofolastat for detection of PCa on a patient and lobe basis, using visual and semiquantitative (tumor-to-background ratio [TBR]) scores, and of LNI was evaluated as well as the correlation of uptake within the gland to Gleason scores (GS) and assessment of the predictive potential of 99mTc-trofolastat uptake for LNI. Results: PCa was detected in 98 patients (94%) with acceptable variability between readers. There was a significantly higher visual score and TBR in positive lobes compared with tumor-negative lobes. Receiver-operating characteristic analysis showed that visual scores more accurately discriminated lobes with GS # 3 1 3 from ≥ 3 1 4, whereas TBRs discriminated high-grade disease from normal lobes better. Visual scores and TBRs correlated significantly with GS. 99mTc-trofolastat SPECT/CT detected LNI with a sensitivity of 50% and specificity of 87%, and TBR values significantly predicted LNI with a sensitivity of 90%. Conclusion: 99mTc-trofolastat SPECT/CT detects PCa with high sensitivity in patients with intermediate- and high-risk PCa compared with histology. It has the potential to be used as a surrogate marker for GS and predict LNI.

AB - 99mTc-trofolastat (99mTc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen, shows high potential to detect prostate cancer (PCa) noninvasively using SPECT. We therefore wanted to assess the performance of 99mTc-trofolastat SPECT/CT in a phase 2 multicenter, multireader prospective study in patients with intermediate- and high-grade PCa, before radical prostatectomy and extended pelvic lymph node (LN) dissection, with histopathology as the gold standard. Methods: PCa patients (n = 105) with an increased risk of LN involvement (LNI) underwent pelvic 99mTc-trofolastat SPECT/CT before radical prostatectomy with extended pelvic LN dissection. The sensitivity of 99mTc-trofolastat for detection of PCa on a patient and lobe basis, using visual and semiquantitative (tumor-to-background ratio [TBR]) scores, and of LNI was evaluated as well as the correlation of uptake within the gland to Gleason scores (GS) and assessment of the predictive potential of 99mTc-trofolastat uptake for LNI. Results: PCa was detected in 98 patients (94%) with acceptable variability between readers. There was a significantly higher visual score and TBR in positive lobes compared with tumor-negative lobes. Receiver-operating characteristic analysis showed that visual scores more accurately discriminated lobes with GS # 3 1 3 from ≥ 3 1 4, whereas TBRs discriminated high-grade disease from normal lobes better. Visual scores and TBRs correlated significantly with GS. 99mTc-trofolastat SPECT/CT detected LNI with a sensitivity of 50% and specificity of 87%, and TBR values significantly predicted LNI with a sensitivity of 90%. Conclusion: 99mTc-trofolastat SPECT/CT detects PCa with high sensitivity in patients with intermediate- and high-risk PCa compared with histology. It has the potential to be used as a surrogate marker for GS and predict LNI.

KW - Tc-trofolastat (Tc-MIP-1404)

KW - Histopathology

KW - Prostate cancer

KW - SPECT/CT

UR - http://www.scopus.com/inward/record.url?scp=85028734919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028734919&partnerID=8YFLogxK

U2 - 10.2967/jnumed.116.187807

DO - 10.2967/jnumed.116.187807

M3 - Article

C2 - 28302763

AN - SCOPUS:85028734919

VL - 58

SP - 1408

EP - 1413

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -